A Phase 3 interventional study of Emicizumab and von Willebrand Factor (VWF) Concentrates in Von Willebrand Disease, Type 3, sponsored by Hoffmann-La Roche. Recruiting at 30 sites in 14 countries. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von Willebrand disease (VWD). Participants on prior standard of care (SOC) on-demand therapy will be assessed via a randomized comparison (Arm A - emicizumab prophylaxis and Arm B - continuation of SOC on-demand therapy), while participants on prior SOC prophylactic therapy (Arm C - emicizumab prophylaxis) will be assessed via intra-participant analysis with data obtained from the preceding non-interventional study (NIS), WP45335 (NCT06883240).
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Inclusion Criteria for Arms A and B:
Additional Inclusion Criteria for Arm C:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are randomized to Arm A, taking on-demand standard of care (SOC) treatment at the time of study entry (and for at least 24 weeks prior to enrollment), will receive emicizumab SC prophylaxis.
Drug: Emicizumab
Participants who are randomized to Arm B, taking on-demand standard of care (SOC) treatment at the time of study entry (and for at least 24 weeks prior to enrollment), will continue to receive their current SOC on-demand treatment until Week 24.
Drug: von Willebrand Factor (VWF) Concentrates · Drug: Factor VIII (FVIII) Concentrates · Drug: von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates · Drug: Bypassing Agents
Participants who enroll in Arm C, taking SOC prophylactic treatment at the time of study entry and for at least 24 weeks of observation during the preceding NIS WP45335, will receive emicizumab SC prophylaxis.
Drug: Emicizumab
Participants in Arms A and C who have completed 24 weeks of emicizumab prophylaxis and who derive benefit from emicizumab will have the opportunity to continue to receive emicizumab prophylaxis in the extension period. Participants in Arm B who have completed 24 weeks of SOC on-demand treatment will have the opportunity to receive emicizumab prophylaxis in the extension period.
Drug: Emicizumab
Participants will receive emicizumab 3 milligrams per kilogram (mg/kg) subcutaneous (SC) injections every week (QW) for the first 4 weeks as loading doses, followed by maintenance doses of emicizumab 3 mg/kg SC once every 2 weeks (Q2W). During the extension period, participants may remain on maintenance dose of emicizumab 3 mg/kg Q2W, or change their emicizumab maintenance regimen to 1.5 mg/kg once every week (QW) or 6 mg/kg once every 4 weeks (Q4W), if they prefer and if agreed by the investigators.
Also known as: Hemlibra, RO5534262, RG6013
Used according to local labeling or local treatment guidelines.
Drug pages: Factor VIII · Antihemophilic factor, human recombinant
Used according to local labeling or local treatment guidelines.
Drug pages: Factor VIII · Antihemophilic factor, human recombinant
Used according to local labeling or local treatment guidelines.
Used according to local labeling or local treatment guidelines.
Annualized Bleed Rate (ABR) for Treated Bleeds in the Randomized Arms
Time frame: From Baseline to at least 24 weeks
ABR for All Bleeds in the Randomized Arms
Time frame: From Baseline to at least 24 weeks
ABR for Treated Spontaneous Bleeds in the Randomized Arms
Time frame: From Baseline to at least 24 weeks
ABR for Treated Joint Bleeds in the Randomized Arms
Time frame: From Baseline to at least 24 weeks
Intra-Participant Comparison of the ABR for Treated Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding Non-Interventional Study (NIS) WP45335
Time frame: From Baseline to at least 24 weeks
Intra-Participant Comparison of the ABR for All Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding NIS WP45335
Time frame: From Baseline to at least 24 weeks
Intra-Participant Comparison of the ABR for Treated Spontaneous Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding NIS WP45335
Time frame: From Baseline to at least 24 weeks
Intra-Participant Comparison of the ABR for Treated Joint Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding NIS WP45335
Time frame: From Baseline to at least 24 weeks
Incidence and Severity of Adverse Events, with Severity Determined According to the World Health Organization (WHO) Toxicity Grading Scale
Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)
Incidence and Severity of Thromboembolic Events
Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)
Incidence and Severity of Thrombotic Microangiopathy Events
Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)
Incidence and Severity of Injection-Site Reactions
Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)
Incidence of Adverse Events Leading to Drug Discontinuation
Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)
Incidence of Severe Hypersensitivity, Anaphylaxis, or Anaphylactoid Reactions
Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)
Incidence of Clinical Laboratory Abnormalities
Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)
Trough Plasma Concentration of Emicizumab at Prespecified Timepoints During the Treatment Period
Time frame: Predose and at prespecified timepoints from first dose of emicizumab until study completion (up to 3 years, 11 months)
Percentage of Participants with Anti-Drug Antibodies (ADAs) to Emicizumab at Baseline and with ADAs to Emicizumab During the Treatment Period
Time frame: Baseline and at prespecified timepoints from first dose of emicizumab until study completion (up to 3 years, 11 months)
Change from Baseline in Respiratory Rate Over Time
Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)
Change from Baseline in Pulse Rate Over Time
Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)
Change from Baseline in Systolic Blood Pressure Over Time
Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)
Change from Baseline in Diastolic Blood Pressure Over Time
Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)
Change from Baseline in Body Temperature Over Time
Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)
Change from Baseline in Electrocardiogram (ECG) Parameters Over Time: QT, QTcF, RR, PR, and QRS Intervals
Time frame: Baseline and study completion (up to 3 years, 11 months)
Change from Baseline in Heart Rate Over Time, as Measured by Electrocardiogram (ECG)
Time frame: Baseline and study completion (up to 3 years, 11 months)
Change from Baseline in the PROMIS-29 Questionnaire Pain Interference Domain Score Over Time
PROMIS-29 stands for Patient-Reported Outcomes Measurement Information System-29
Time frame: Baseline and at prespecified timepoints until study completion (up to 3 years, 11 months)
Change from Baseline in the PROMIS-29 Questionnaire Fatigue Domain Score Over Time
PROMIS-29 stands for Patient-Reported Outcomes Measurement Information System-29
Time frame: Baseline and at prespecified timepoints until study completion (up to 3 years, 11 months)
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Jun 2025 (actual). Primary completion is estimated for Oct 2027, 27 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Apr 2027 → Oct 2027 and completion Apr 2029 → Sep 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emicizumab
von Willebrand Disease, Type 3